Basel, Switzerland

Philip Barth

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2023

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Philip Barth in Pharmaceutical Aerosols

Introduction

Philip Barth is an accomplished inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of aerosol dosage forms. With a total of two patents to his name, Barth's work focuses on innovative solutions for pulmonary diseases.

Latest Patents

Barth's latest patents include a groundbreaking invention titled "Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof." This invention relates to pharmaceutical aerosols that comprise a β-hairpin peptidomimetic, which has demonstrated inhibitory activity against human neutrophil elastase. The invention is designed for the prevention, management, or treatment of various pulmonary diseases, including alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), and chronic obstructive pulmonary disease (COPD). The pharmaceutical composition can be administered in solid or liquid forms, providing a versatile approach to treating conditions mediated by human neutrophil elastase activity.

Career Highlights

Philip Barth is currently associated with Polyphor AG, a company known for its innovative pharmaceutical solutions. His work at Polyphor AG has allowed him to focus on developing advanced therapeutic options for patients suffering from serious lung conditions.

Collaborations

Barth collaborates with notable colleagues, including Christian Ludin and Manfred Keller, who contribute to the innovative environment at Polyphor AG. Their combined expertise enhances the research and development efforts within the company.

Conclusion

Philip Barth's contributions to the field of pharmaceuticals, particularly through his innovative patents, highlight his commitment to improving treatment options for pulmonary diseases. His work continues to pave the way for advancements in aerosol therapies, benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…